501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies to Beta Test Marijuana Breathalyzer with Occupational
Health Clinic in Southern California to Meet Workplace Drug Testing
Needs
Cannabix is developing the Cannabix Marijuana Breathalyzer devices
to give law enforcement and employers a tool to enhance public
safety
Vancouver, British
Columbia -- November 23,
2020 -- InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC PINK: BLOZF) (the "Company or Cannabix") developer of
the Cannabix Marijuana Breathalyzer for law enforcement and the
workplace, is pleased to report that it plans
to begin beta testing its version 3.0 THC Breath Analyzer
("THCBA")
in southern California
with an occupational health care provider located in Newport
Beach. Cannabix
expects
to
deliver
its latest version of the THCBA to Alipour Medical Centre
early
in the new year. Alipour
Medical Centre provides drug and alcohol testing services to a
number of local employers in the state.
The THCBA is an ideal device for employers and other markets who
are seeking a way to quickly, easily and non-invasively test for
recent use of ?9-tetrahydrocannabinol
("THC")
- the psychoactive component of marijuana that causes impairment.
Cannabix will be seeking additional organizations for beta testing
and welcomes interested parties to contact us via
our website (cannabixtechnologies.com).
Employers
everywhere are struggling with the limitations of current drug
testing technology in identifying recent use of marijuana that may
be causing impairment during work hours and differentiating this
from recreational and medical use during nonwork
hours/days.
The Cannabix device
allows for more relevant THC detection from breath allowing
employers to create an onsite regiment whereby they can perform
pre-access testing for recent use of marijuana before and during
work hours, instead of testing for drug use when employees are not
at work. Cannabix will be beta testing its device in order to
continue training the device's machine learning database and
improve user experience through testing feedback.
The
THCBA has been built to provide easy to understand screen prompts
for the positive and negative detection of THC in breath in a
portable manner, and can be administered without extensive
training.
Current forms of
testing for marijuana use can identify THC ranging from minutes to
days prior to actual use, making it impossible to show the
difference between the two. Studies¹
have shown that breath is a better indicator of impairment than
saliva, blood, or urine because THC is present in breath for a
relatively short period of time (1-3 hours); whereas, it is
excreted at detectable levels in other body fluids for many hours,
days, or even weeks after smoking. This short time period of
detection in breath aligns with the peak impairment
window.
Dr. Nima Alipour,
CEO of Alipour Medical Corp, stated, "We are very pleased
to be using one of the world's first marijuana breathalyzers in our
medical facility. We know first-hand how the legalization of
marijuana has affected employers in our state.
As
occupational health practitioners based in Orange County, we
understand the challenges that employers are facing in providing
relevant drug testing for existing
and new employees. We advise
corporations on how best to keep their workforce safe; identifying
safety issues as they pertain
to impairment, while taking into account employee rights in an
environment of state legalization. Alipour
Medical prides itself on deploying cutting edge technology in our
practice and we look forward to helping with research, and
ultimately beta testing devices alongside Cannabix
Technologies in California."
Parties interested
in working with Cannabix to beta-test its Cannabix Marijuana
Breathalyzer are encouraged to contact the Company at info@cannabixtechnologies.com
(1) Olla
P, Ishraque
MT,
Bartol
S. 2020.
Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration
Trends Postcannabis
Exposure
in Medical Cannabis Patients. Cannabis and Cannabinoid Res.;
99-104.
Himes S.
et al. 2013. Cannabinoids in Exhaled Breath following Controlled
Administration of Smoked Cannabis. Clinical Chemistry;
1780–1789.
Beck
O, Sandqvist
S,
Dubbelboer
I,
Franck J. 2011. Detection of delta9-tetrahydrocannabinol in exhaled
breath collected from cannabis users. J Anal Toxicol;
35:541– 4.
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing accurate,
durable, portable tools to market to enable detection of
marijuana-impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects usage, days or even weeks
earlier. The devices will also be useful for other practical
applications such as testing employees in the workplace where
impairment by THC can be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including:
(i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public
announcements and filings. There is no assurance that the marijuana
breathalyzer business will provide any benefit to the Company, and
no assurance that any proposed new products will be built or
proceed. There is no assurance that existing "patent pending"
technologies licensed by the Company will receive patent status by
regulatory authorities. The Company is not currently selling
commercial breathalyzers. Actual results and future events could
differ materially from those anticipated in such information. These
and all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.